Open AccessImpact of Tocilizumab (Anti–IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection
Author(s) -
Beomju Shin,
Matthew J. Everly,
Hao Zhang,
Jua Choi,
Ashley Vo,
Xiaohai Zhang,
Edmund Huang,
Stanley C. Jordan,
Mieko Toyoda
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002895
Subject(s) - antibody , immunology , tocilizumab , medicine , immunoglobulin g , rituximab , immune system , elispot , kidney transplantation , kidney , cd8 , rheumatoid arthritis
Chronic antibody-mediated rejection (cAMR) results in the majority of renal allograft losses. Currently, there are no approved therapies. We recently reported on clinical use of tocilizumab (TCZ) for treatment of cAMR in HLA-sensitized kidney transplant patients. IgG1 and IgG3 subclasses of IgG are potent effectors of complement- and antibody-dependent cellular cytotoxicity, which are critical mediators of AMR. Here, we examined the impact of TCZ treatment for cAMR on total IgG, IgG1-4 subclasses, and anti-HLA-IgG (total and subclasses).